Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Adherence and persistence with medication regimens is highly relevant to disease outcomes • Adherence to a medication regimen is generally defined as the extent to which patients take medications as prescribed by their health care provider.1 • Methods that can be used to confirm adherence to a medication regimen include: monitoring of pill count, monitoring of prescription refill rate, and patient use of “smart” pill bottles, but these are all indirect measures. • Nonpersistence with antihypertensive therapy is associated with an increased risk of myocardial infarction and stroke.2 1. Osterberg L, Blasche T. N Engl J Med. 2005;353:487-497. 2. Breekveldt-Postma NS et al. Curr Med Res Opin. 2008;24:121-127. Prescription of a single-pill combination is associated with improved adherence rates compared with free-combination therapy SPC (ACE inhibitor + CCB) (n=2839) 88% P<0.0001 Free combination (ACE inhibitior + CCB) (n=3367) 69% 0% 20% 40% 60% 80% Medication possession ratio (MPR)* *Defined as the total number of days of therapy for medication dispensed/365 days of study follow-up ACE, angiotensin-converting enzyme; CCB, calcium channel blocker; SPC, single-pill combination Gerbino PP, Shoheiber O. Am J Health System Pharm. 2007;64:1279-1283. 100% A new device* approved by the FDA1 can be included in antihypertensive pills to monitor the adherence to treatment • The ingestible sensor is made entirely of ingredients found in food and is activated upon ingestion to transmit a unique number which is captured by an external patch. • The ingestible sensor does not require any battery or antenna; it is powered by the contact with stomach fluids. • The ingestible sensor can be embedded in a drug product and can be used for directly confirming medication adherence, as part of a networked wellness system. • The networked system has already been tested in hypertension and heart failure populations. Edible sensor attached directly to a tablet * The Ingestion Event Marker (IEM), by Proteus Health. 1. FDA approves digestible microchips to be placed in pills. Medscape. August 3, 2012.